Launch of Retail Offer

The Board of Eden Research plc (the "Company") is pleased to announce a retail offer via BookBuild (the "Retail Offer") of new ordinary shares ("Ordinary Shares") of £0.01 each in the capital of the Company (the "Retail Offer Shares") at an issue price of 4.0 pence per Retail Offer Share (the "Issue Price").

In addition to the Retail Offer, the Company announced earlier today, a proposed Fundraising, pursuant to which it proposes to raise, subject to certain conditions £10.7 million (before expenses). The Fundraising consists of the Firm Placing, the Firm Subscription (together the "Firm Capital Raising") and the Retail Offer which will raise up to £3.6 million in aggregate (before expenses), assuming full take up of the Retail Offer, as well as the Conditional Placing which will conditionally raise £7.6 million in aggregate (before expenses). A separate announcement has been made regarding the Firm Capital Raising and Conditional Placing and their terms.

In recognition of their continued support to the Company, the Board believes that the Retail Offer provides the Company's longstanding and supportive Shareholders with an opportunity to participate in the Fundraising. The Issue Price represents a premium of approximately 2.6 per cent to the closing share price of 3.9 pence per existing Ordinary Share on 30 January 2026.

For the avoidance of doubt, the Retail Offer is not part of the Firm Capital Raising or Conditional Placing. Full details of the Fundraising, including the background to, and reasons for the Firm Capital Raise and the Conditional Placing and the Retail Offer, is included in the separate announcement released by the Company earlier today.

The Retail Offer is conditional on the passing of the Resolutions by Shareholders at the General Meeting, completion of the Firm Capital Raising and First Admission. The Firm Capital Raising and the Conditional Placing are not conditional upon the Retail Offer. Admission of the Retail Offer Shares pursuant to the Retail Offer is expected to take place as part of the First Admission on 19 February 2026.

The net proceeds of the Firm Capital Raising and any proceeds of the Retail Offer will be used principally to advance and expedite the development, registration and commercialisation of Eden's insecticide formulation and the development of a new fungicide which tackles Late Blight, the most important fungal disease of potatoes.

Subject to the satisfaction of the Conditions, the Conditional Placing will be used to develop and register the fungicide for Late Blight, development of broad acre crop fungicide for Septoria in wheat and commercial and operational scale up, as described in more detail in the announcement of the Fundraising earlier today.

Expected Timetable in relation to the Retail Offer

Retail Offer

The Company values its retail shareholder base, which has supported the Company alongside institutional investors since IPO. Given the support of retail shareholders, the Company believes that it is appropriate to provide its retail shareholders in the United Kingdom the opportunity to participate in the Retail Offer. The Company is therefore making the Retail Offer available in the United Kingdom through the financial intermediaries which will be listed, subject to certain access restrictions, on the following website: https://www.bookbuild.live/deals/J19Z21/authorised-intermediaries

The Retail Offer will be open to eligible investors in the United Kingdom at 13:00 pm on 2 February 2026. The Retail Offer is expected to close at 12:00 pm on 5 February 2026. Investors should note that financial intermediaries may have earlier closing times. The Retail Offer may close early if it is oversubscribed.

There is a minimum subscription of £100.00 per investor under the terms of the Retail Offer which is open to investors in the United Kingdom subscribing via the intermediaries which will be listed, subject to certain access restrictions, on the following website: https://www.bookbuild.live/deals/J19Z21/authorised-intermediaries

Key Investment Risks

Unless otherwise defined herein or the context requires, capitalised terms used in this announcement have the meanings given to them in the Fundraising announcement released earlier today under RNS number 3600R.

UK Product Governance Requirements

EU Product Governance Requirements